CBN vs CBD
- CBN
- Lab activity only: a potent TRPA1 agonist and desensitiser, and antibacterial in vitro Demonstrated; human sleep trials missed their pre-specified endpoints Not supported
- CBD
- The most-studied cannabinoid; a purified-CBD prescription medicine is approved for certain rare seizure disorders (a regulatory fact that does not extend to consumer products); consumer wellness claims mostly not established — catalogue in progress
From the evidence status row of the table below.
The two start life far apart. CBN (cannabinol) forms as THC ages and oxidizes, while the plant makes CBD (cannabidiol) directly and in quantity. Neither is meaningfully intoxicating, yet their chemistry and evidence differ, and CBN carries a real drug-test risk. The sleep benefit both are sold on is not established for either. Established
Whose claims are whose. Chemical identity, origin, intoxication status and lab behaviour are verified science and carry an evidence grade. Claims about effects or benefits (sleep, sedation, relaxation) come from others and are reported as their claims; CBG Atlas does not make, adopt or affirm them. Where verified evidence runs out, the entry reads "catalogue in progress." Grades: the six-rung evidence ladder. Not medical, legal, or professional advice.
At a glance
| CBN | CBD | |
|---|---|---|
| Full name | CBNCannabinol | CBDCannabidiol |
| Formula / CAS | CBNC₂₁H₂₆O₂ · CAS 521-35-7 · CID 2543 · MW ≈310.43 | CBDC₂₁H₃₀O₂ · CAS 13956-29-1 · MW ≈314.46 |
| Intoxicating? | CBNNon-intoxicating, or weakly intoxicating at most; its cannabinoid-receptor activity in lab studies is weak Demonstrated | CBDNon-intoxicating Established |
| General legal status (2026; not legal advice) | CBNHemp-derived CBN is generally legal federally in the US under the 2018 Farm Bill if it contains ≤0.3% delta-9 THC by dry weight; varies by state | CBDSame Farm Bill framework; the FDA has not approved CBD as a food or supplement; varies by state |
| Commonly marketed for (attributed) | CBNMarketed as a sleep or sedation aid, often blended with melatonin (a third-party claim) | CBDMarketed for stress, relaxation, sleep and general wellness (third-party claims) |
| Evidence status (graded) | CBNLab activity only: a potent TRPA1 agonist and desensitiser, and antibacterial in vitro Demonstrated; human sleep trials missed their pre-specified endpoints Not supported | CBDThe most-studied cannabinoid; a purified-CBD prescription medicine is approved for certain rare seizure disorders (a regulatory fact that does not extend to consumer products); consumer wellness claims mostly not established — catalogue in progress |
The six rungs, and the words each one permits
- grade: Established
- Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
- grade: Demonstrated
- Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
- grade: Emerging
- An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
- grade: Low
- Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
- grade: Hypothesized
- Proposed and plausible — but not yet shown. “proposed mechanism”
- grade: Not supported
- Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
- Catalogue in progress
- Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.
A grade rates the support for a claim across the literature, never a single study. How we grade evidence.
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- CBN: no graded interaction in our registry. CBD: damps activation (negative allosteric modulator; drawn as two bars), in vitro grade: Demonstrated study type: In vitro Laprairie 2015.
- CB2 cannabinoid receptor
- CBN: no graded interaction in our registry. CBD: blocks what activates it (antagonist of CB1/CB2 agonists), in a review, no rung of its own study type: Review Pertwee 2008.
- α2-adrenoceptor
- CBN: no graded interaction in our registry. CBD: no graded interaction in our registry.
- 5-HT1A serotonin receptor
- CBN: no graded interaction in our registry. CBD: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Russo 2005.
- TRPV1 and TRPV2 ion channels
- CBN: no graded interaction in our registry. CBD: no graded interaction in our registry.
- TRPM8 ion channel
- CBN: no graded interaction in our registry. CBD: no graded interaction in our registry.
What the evidence supports
The chemistry of these two is settled. The trouble starts at the bedside table, where both are sold, and at the drug-test cup, where CBN can spring a surprise.
- Neither is meaningfully intoxicating. CBN is non-intoxicating, or weakly intoxicating at most, with only weak cannabinoid-receptor activity in lab studies; CBD is non-intoxicating. Established / Demonstrated
- Origin is the real divide. CBN is what THC breaks down into as it oxidizes: oxygen, heat and light work on aging THC, which is why older cannabis holds more CBN. The plant makes CBD directly, from its acid CBDA. Established
- Verified lab activity (CBN). In vitro, CBN is a potent TRPA1 agonist and desensitiser and showed antibacterial activity against MRSA (De Petrocellis 2011; Appendino 2008), cell-level findings rather than demonstrated human benefits. Demonstrated
- CBD-specific mechanisms. Our registry does not yet hold a verified receptor anchor for CBD, so its mechanisms here are catalogue in progress, even though in the wider literature it is the most-studied cannabinoid in humans.
- Sleep and relaxation. Here the money and the evidence point in opposite directions. Both are marketed for sleep. CBN's sleep claim has been tested in people, and those trials missed the endpoints they set in advance (Bonn-Miller 2024; Lavender 2026), a negative result rather than a missing one Not supported. For CBD, our registry contains no controlled human trial showing a sleep benefit (catalogue in progress). CBN's name as the "sleep cannabinoid" likely owes more to the terpenes and oxidation of aged cannabis than to CBN itself, so a CBN sleep product is selling a reputation the trials did not bear out.
- Drug testing. CBN can cross-react with the THC immunoassays used in standard screening, and CBN products may contain trace THC, so a positive test is a real possibility. CBD isolate sits outside what the test looks for, though full- or broad-spectrum CBD can carry trace THC that tests detect. Established
- Safety & cardiovascular. CBN-specific human safety data are thin (catalogue in progress), and cannabinoids may change how the body processes some medicines. Cardiovascular note: some cannabinoids — notably CBG — act at the α2-adrenoceptor (Cascio 2010), a target linked to blood-pressure regulation; anyone with blood-pressure concerns or on cardiovascular medication should consult a clinician before using any cannabinoid product. Established (α2 anchor) / catalogue in progress (CBN safety)
Common questions
Is CBN or CBD better for sleep?
Neither has been shown to help sleep in controlled human studies, though both are widely sold for it. CBN at least had its day in court: human trials tested the claim and missed the endpoints they set in advance (Bonn-Miller 2024; Lavender 2026), a negative result rather than a gap. For CBD, our registry holds no trial that establishes a sleep benefit. Both are non-intoxicating. Not supported · CBN; for CBD, catalogue in progress (Not medical advice.)
What's the main difference between CBN and CBD?
Where they come from, and the chemistry that follows. CBN (C₂₁H₂₆O₂) is the breakdown product of THC, formed as THC oxidizes with oxygen, heat and light over time; CBD (C₂₁H₃₀O₂) is made by the plant directly from its acid, CBDA. Both are non-intoxicating, and CBD has far more human research behind it. Established
Will CBN or CBD make me fail a drug test?
Either one could, mostly because of trace THC. CBN adds a second route of its own: it is chemically close to THC and can cross-react with the THC immunoassays used in standard screening. CBN products and full- or broad-spectrum CBD products can also carry trace THC that tests detect, so anyone who is drug-tested is safest avoiding both. Established
Is CBN just aged CBD?
No. CBN comes from aged THC, and the CBD version is a common mix-up. Over time, oxygen, heat and light slowly oxidize THC into CBN, which is why older cannabis contains more of it. CBD is a separate molecule the plant builds directly, with no part in making CBN. Established
Are CBN and CBD legal?
Generally yes in the US, as of 2026. Under the 2018 Farm Bill, hemp-derived CBN and CBD are generally federally legal when the product contains 0.3% delta-9 THC or less by dry weight. State laws differ, and the FDA has not approved CBD as a food or supplement. General information, not legal advice. Established
Is CBN more sedating than CBD?
No reliable evidence ranks one above the other. Both are non-intoxicating and sold for relaxation, yet neither has an established sedative effect in controlled human studies, and CBN's drowsy reputation likely belongs to the terpenes and oxidation of aged cannabis rather than to CBN itself. Our registry contains no head-to-head trial of the two, so a claim that one relaxes you more is marketing, an absence in the record rather than a finding against either. No primary evidence · catalogue in progress (Not medical advice.)
Sources
- De Petrocellis 2011 — PMID 21175579 — CBN is a potent TRPA1 agonist/desensitiser, in vitro. Grade: Demonstrated.
- Appendino 2008 — PMID 18681481 — antibacterial activity, including against MRSA, in vitro. Grade: Demonstrated.
- Cascio 2010 — PMID 20002104 — CBG acts at the α2-adrenoceptor (and 5-HT1A); cited here only to anchor the cardiovascular/blood-pressure caution. Grade: Demonstrated.
- Chemical identity (Established). CBN: C₂₁H₂₆O₂ · MW ≈310.43 · CAS 521-35-7 · CID 2543 · the aromatic product of THC oxidation. CBD: C₂₁H₃₀O₂ · MW ≈314.46 · CAS 13956-29-1 · non-intoxicating, made by the plant from CBDA.
- Sleep / sedation / relaxation: not established in controlled human studies for either compound, and presented only as third-party claims (catalogue in progress). Binding and potency figures, and dosing, are left out.
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.
Verified sources: De Petrocellis 2011 (PMID 21175579) · Appendino 2008 (PMID 18681481) · Cascio 2010 (PMID 20002104).
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons